The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis of Pluvicto.

Novartis admitted the email broke several rules set out in the U.K. marketing code. In a long response to the PMCPA, the ...

Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted ...

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive mHSPC: Basel Tuesday, June 3, 2025, 12:00 Hrs [IST] ...

The latest results, which J&J shared at the 2025 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this ...

Find insight on Novarti, Sanofi and more in the latest Market Talks covering Health Care.

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...